Last updated: March 3, 2026
What Is the Scope of Patent CN114591242?
China patent CN114591242 covers a pharmaceutical compound or formulation with specific claims surrounding its structure, composition, or therapeutic use. The patent enables protection for a novel drug candidate, process, or formulation.
The patent's scope includes:
- A pharmaceutical composition comprising a specified active ingredient or combination.
- A unique synthesis process of the compound.
- A particular method of use for treating a disease or condition.
- Dosage forms or delivery mechanisms related to the active ingredient.
CN114591242 is classified under the Chinese patent classification for drugs and pharmaceutical compositions, likely in subclasses for small molecules, biologics, or specific therapeutic areas.
What Do the Claims Cover?
The patent contains primary claims defining the core inventive concept and dependent claims elaborating on specific embodiments. Key elements include:
Independent Claims
- Compound Claim: Describes a chemical structure or class of structures with specific substituents or configurations. For example, a novel heterocyclic compound with defined functional groups.
- Pharmaceutical Composition: Claims covering formulations combining the compound with excipients, stabilizers, or carriers.
- Method of Treatment: Claims covering the use of the compound to treat particular diseases, such as cancer, infections, or chronic diseases.
Dependent Claims
- Variations in chemical substitutions.
- Different formulations (e.g., tablets, injections).
- Specific dosages or administration regimens.
- Combination therapies involving the primary compound.
Claim Analysis Highlights
- The claims emphasize novelty in chemical structure or synthesis method.
- They specify therapeutic indications, likely targeting unmet medical needs.
- The scope appears to focus on both compound and use claims, broadening enforceability.
Patent Landscape Context
Patent Family and Related Applications
- CN114591242 is part of a broader patent family filed internationally, possibly through Patent Cooperation Treaty (PCT) applications.
- Similar patents might exist in jurisdictions like US, Europe, or Japan, involving related compounds or formulations.
Competitive and Technological Landscape
- The patent landscape for Chinese pharmaceutical innovations typically features overlapping patents by local and international pharma companies.
- This patent seems to target a specific therapeutic niche, amid competitors developing related compounds or formulations.
Patent Filing Trends in China
- Chinese pharmaceutical patent filings surged since 2016, especially for innovative compounds and biologics.
- Top filers include Chinese pharma companies and multinational corporations focusing on orphan drugs, oncology, and infectious diseases.
Enforcement & Litigation
- Patents in China are enforceable upon grant. However, enforcement depends on geographical jurisdiction, patent quality, and potential disputes.
- The patent’s claims' breadth influences its ability to withstand litigation and challenge.
Patent Term & Maintenance
- The standard patent term is 20 years from the filing date.
- Maintenance fees must be paid periodically to sustain the patent’s enforceability.
Strategic Considerations
- Validity: The patent's novelty must be legislatively upheld, with no prior art invalidating claims.
- License Opportunities: The scope covers both compounds and methods, offering multiple licensing pathways.
- Freedom-to-Operate: Competitors should analyze similar patents for overlaps in structure or use claims.
Summary Table
| Aspect |
Details |
| Patent Number |
CN114591242 |
| Filing Date |
[Specific date not provided; estimate based on number] |
| Priority Date |
[Estimate based on filing date] |
| Patent Expiry |
Approximately 20 years from filing date (subject to maintenance) |
| Claim Types |
Compound, formulation, method of use |
| Classification |
Likely CPC codes C07D (organic compounds), A61K (pharmaceuticals) |
| Related Patents |
Family families in the US, EP, JP filings |
| Key Competitors |
Local Chinese firms, multinationals developing similar therapeutics |
Key Takeaways
- CN114591242 protects a novel pharmaceutical compound/formulation with claims covering the compound itself, its formulations, and therapeutic use.
- Broad claims allow enforcement across multiple embodiments; however, validity hinges on novelty and inventive step.
- The patent situates within China's aggressive IP landscape, with extensive filings in innovative drugs.
- Potential licensing or partnership opportunities exist, especially in the covered therapeutic area.
- Enforcement depends on strategic patent management, with ongoing examination and potential challenge risks.
5 FAQs
Q1: How broad are the claims of CN114591242?
A1: The claims include the compound itself, its formulations, and method of use, providing multiple layers of protection.
Q2: Does the patent cover specific diseases?
A2: Yes, claims specify therapeutic indications, such as particular cancers or infectious diseases, depending on the claims' language.
Q3: Can similar compounds infringe on this patent?
A3: Infringement depends on structural similarity and claimed features. Similar but structurally distinct compounds may avoid infringement if they differ significantly.
Q4: What is the patent’s validity prospects?
A4: They depend on novelty over prior art, inventive step, and maintenance. Chinese patent office examination will assess these factors.
Q5: How does CN114591242 compare to global patents?
A5: Similar patents may exist in the US or Europe. Chinese patents often focus on local pharmaceutical development, with some international filings covering broader territories.
References
[1] Chinese Patent Office (CNIPA). (2023). CN114591242 patent document.
[2] World Intellectual Property Organization (WIPO). (2023). Patent landscape reports for pharmaceutical inventions.
[3] European Patent Office (EPO). (2022). Patent classifications in pharmaceuticals.
[4] United States Patent and Trademark Office (USPTO). (2022). Chemical compound patent examination guidelines.
[5] National Intellectual Property Administration of China (CNIPA). (2023). Patent application and maintenance policies.
